Oswald, Laura B.
Bloomer, Amanda
Li, Xiaoyin
Jean-Baptiste, Esther
Trujillo, Gillian
Felder, Seth
Small, Brent J.
Ose, Jennifer
Hardikar, Sheetal
Strehli, Ildiko
Huang, Lyen C.
Mooney, Kathi
Mutch, Matthew G.
Chao, Dante
Cohen, Stacey A.
Karchi, Meghana
Wood, Elizabeth H.
Damerell, Victoria
Loroña, Nicole C.
Gong, Jun
Toriola, Adetunji T.
Li, Christopher I.
Shibata, David
Schneider, Martin
Gigic, Biljana
Figueiredo, Jane C.
Jim, Heather S. L.
Ulrich, Cornelia M.
Siegel, Erin M.
Funding for this research was provided by:
Moffitt Cancer Center Department of Epidemiology Innovation Award
National Institutes of Health, National Cancer Institute (U01CA206110, U01CA206110, R01CA254108, U01CA206110, U01CA206110, U01CA206110)
German Ministry of Education and Research (01KT1503, 01KT1503)
National Institutes of Health, National Institute of Nursing Research (R01NR018762)
Florida Department of Health Bankhead Coley Award (09BN-13)
Article History
Received: 22 January 2024
Accepted: 16 April 2024
First Online: 19 April 2024
Declarations
:
: This study was performed in line with the Declaration of Helsinki. Approval was granted by the ethics committee of each recruitment site: Moffitt Cancer Center (USF104189, USF108437), University of Tennessee Health Science Center (16–04626-FB), Washington University School of Medicine (201610032), Huntsman Cancer Institute (IRB_00077147), Cedars-Sinai Medical Center (Pro000464423, CR00012892), Fred Hutchinson Cancer Center (6407), and University of Heidelberg (300/2001, S-134/2016).
: Informed consent to participate and to have de-identified and aggregate study data published was obtained from all individual participants included in this study.
: Dr. Felder reports an advisory role for GSK and research funding from ViewRay and Natera. Dr. Cohen reports personal fees and grants from Pfizer and personal fees from Taiho, Bayer, Regeneron, Biomea, Eisai, Delcath, Isofol, and GSK. Dr. Gong reports advisory/consulting for Aveo, Basilea, Bayer, EMD Serono, Elsevier, Exelixis, HalioDx, Janssen, Pfizer, Inc, QED Therapeutics, Seagen, and Taiho. Dr. Jim reports grant funding from Kite Pharm and a consultant role for SBR Bioscience. Dr. Ulrich reports oversight over research funded by several pharmaceutical companies in her role as Cancer Center Director, but she has not received funding directly herself. The other authors have no competing interests to disclose.
: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.